Physician profile
Alfredo Ramirez
NPI 1427136894
$3,551.68
in general payments reported to CMS, 2019-2025
33 companies · $57.27 in 2025
The $57.27 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $451 · 2021: $789 · 2022: $270 · 2023: $671 · 2024: $222 · 2025: $57.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $731.61 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $467.31 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $281.04 | 2021-2023 | |
| Glaxosmithkline, LLC. | $255.61 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Mylan Specialty L.P. | $233.43 | 2020-2024 | Yupelri |
| Amgen INC. | $168.15 | 2019-2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $150.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.13 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $103.26 | 2019 | |
| Tela Bio, INC. | $103.00 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $95.12 | 2020 | |
| Merck Sharp & Dohme LLC | $91.69 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $80.01 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $74.70 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.20 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $57.27 | 2025 | |
| Lilly USA, LLC | $55.15 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.81 | 2021-2023 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $50.09 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $38.59 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $35.34 | 2020 | |
| Dexcom, INC. | $28.63 | 2022 | |
| Dermira, INC. | $27.50 | 2020 | |
| Esperion Therapeutics, INC. | $22.79 | 2020 | |
| Pfizer INC. | $22.45 | 2024 | |
| Abbvie INC. | $20.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.24 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $18.60 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.25 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.96 | 2022 | |
| Medtronic, INC. | $16.09 | 2021 | |
| Abbott Laboratories | $15.22 | 2021 | |
| Exact Sciences Corporation | $14.81 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.